Abstract
A new thought-provoking report on performance, capabilities, goals and strategies of the major competitors in the worldwide pharmaceutical market
- Available by Company !
- Contains nearly 1,200 pages and tables
- Includes a 25-page Worldwide Market Overview
A strategic assessment of the competitive environment is unquestionably one of the highest priority management responsibilities crucial to business survival, growth and profitability, Timely and factual competitive intelligence is vital to the success of all business functions, especially Planning, Marketing, R&D and Manufacturing. in a highly dynamic and fragmented pharmaceutical market, besieged by intense competition, the rapid pace of technological innovations, and the uncertainty regarding future government regulations, the ability to anticipate new competitive product introductions and marketing strategies is particularly important..... and spells the difference between success and failure.
The Top10, a unique series of market intelligence studies introduced by VENTURE PLANNING GROUP in 1987, is designed to provide the pharmaceutical industry executives with strategically significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
The study' s major objectives include:
- To establish a comprehensive, factual, annually-updated and cost-effective information base on performance, capabilities, goals and strategies of the world' s leading pharmaceutical companies.
- To help current suppliers realistically assess their financial, marketing and technological capabilities vis-a-vis leading competitors.
- To assist potential market entrants in evaluating prospective acquisitions and joint venture candidates.
- To complement organizations' internal competitor information gathering efforts by providing strategic analysis, data interpretation and insight.
- To identify the least competitive market niches with significant growth potential.
Methodology
VENTURE PLANNING GROUPS DATABASE
VPG' s proprietary data files contain current information on major pharmaceutical companies, technologies, products and executives worldwide. These files, developed in the course of over 100 syndicated and numerous single-client studies, were thoroughly searched to retrieve any information pertinent to the Top 1O companies' capabilities and strategies.
SECONDARY INFORMATION SOURCES
A comprehensive review of the Top 1O companies' product and financial literature, business and technical periodicals, and pertinent industry analyst reports was conducted.
Table of Contents
The report provides the following information:
SECTION I: EXECUTIVE SUMMARY
- A 5-10 page synopsis of key sections.
SECTION II: BUSINESS ORGANIZATION
- History of the company' s pharmaceutical business evolution, which is important to understanding the corporate culture, management mentality, and strategies.
- Most recent M&A activity and significant organizational changes Current organizational structure.
SECTION III: SENIOR MANAGEMENT
- Names, titles, and background of senior managers.
SECTION IV: FACILITIES AND EMPLOYEES
- Major administrative, manufacturing, and R&D facilities in the U.S. and abroad.
- Manufacturing practices.
- New plants under construction.
- U.S. and international work force size and distribution.
SECTION V:TECHNOLOGICAL KNOW-HOW
- Internally developed and acquired technologies, processes, and related capabilities.
- Know-how in biotechnology and other pertinent fields, Proprietary technologies and patent litigations.
SECTION VI: PRODUCT PORTFOLIO ANALYSIS
- Extensive review of major ethical, OTC,and generic drugs.
- Most recent new drug introductions and indications.
SECTION VII: MARKETING TACTICS
- Sales force size and structure in the U.S., Europe, Japan, and other regions.
- Major sales office locations.
SECTION VII: MARKETING TACTICS
- Sales force in the U.S., Europe, and other regions.
- Distribution strategies.
- Major promotional tactics.
SECTION VIII: FINANCIAL ANALYSIS
- The 2006 U.S. and international sales and operating profit estimates by division, geographic region, therapeutic category, and individual drug.
- The 2002-2006 sales and operating profit performance.
SECTION IX:R&D EXPENDITURES AND MAJOR PROGRAMS
- The 2006 R&D budget.
- Research facilities and staff.
- New technologies, drugs, and indications in development, including their phase and anticipated introduction dates.
SECTION X: COLLABORATIVE ARRANGEMENTS
- Major joint venture, distribution, OEM, and licensing partners, both industrial and academic.
- Terms of collaborative agreements and specific products involved.
SECTI0N XI: STRATEGIC DIRECTION
- Major strengths and weaknesses.
- Business, new product development, and marketing objectives and strategies.
- Anticipated acquisitions, joint ventures, and divestitures.
COMPARATIVE ANALYSIS
In this section of the report, the Top 1O companies are ranked according to the following criteria:
- Worldwide sales and rank products.
- Operating profit and margins.
- R&D expenditures.
- Worldwide sales force size.
